Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial

BACKGROUND: Platinum/fluoropyrimidine regimens are the backbone of first-line chemotherapy for advanced gastric cancer (AGC). However response rates to first line chemotherapy range from 30 to 50% and disease progression occurs after 4–6 cycles. The optimal duration of first-line therapy is still un...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Bartolomeo, Maria, Niger, Monica, Morano, Federica, Corallo, Salvatore, Antista, Maria, Tamberi, Stefano, Lonardi, Sara, Di Donato, Samantha, Berardi, Rossana, Scartozzi, Mario, Cardellino, Giovanni Gerardo, Di Costanzo, Francesco, Rimassa, Lorenza, Luporini, Alberto Gianluigi, Longarini, Raffaella, Zaniboni, Alberto, Bertolini, Alessandro, Tomasello, Gianluca, Pinotti, Graziella, Scagliotti, Giorgio, Tortora, Giampaolo, Bonetti, Andrea, Spallanzani, Andrea, Frassineti, Giovanni Luca, Tassinari, Davide, Giuliani, Francesco, Cinieri, Saverio, Maiello, Evaristo, Verusio, Claudio, Bracarda, Sergio, Catalano, Vincenzo, Basso, Michele, Ciuffreda, Libero, De Vita, Ferdinando, Parra, Hector Soto, Fornaro, Lorenzo, Caporale, Marta, de Braud, Filippo, Pietrantonio, Filippo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440108/
https://www.ncbi.nlm.nih.gov/pubmed/30922323
http://dx.doi.org/10.1186/s12885-019-5498-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440108/
https://www.ncbi.nlm.nih.gov/pubmed/30922323
http://dx.doi.org/10.1186/s12885-019-5498-3

Ejemplares similares